Regulatory approval

Published by the European Medicines Agency.

The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.

This is written in the approval document as:

SPRYCEL is indicated for the treatment of adult patients with Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

Citation

Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib